WallStSmart

IQVIA Holdings Inc (IQV)vsPrenetics Global Ltd (PRE)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

IQVIA Holdings Inc generates 17553% more annual revenue ($16.31B vs $92.39M). IQV leads profitability with a 8.3% profit margin vs -63.1%. IQV earns a higher WallStSmart Score of 72/100 (B).

IQV

Strong Buy

72

out of 100

Grade: B

Growth: 6.0Profit: 7.0Value: 10.0Quality: 4.3
Piotroski: 4/9Altman Z: 1.33

PRE

Avoid

35

out of 100

Grade: F

Growth: 6.0Profit: 2.0Value: 5.0Quality: 5.0
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

IQVUndervalued (+49.1%)

Margin of Safety

+49.1%

Fair Value

$348.46

Current Price

$165.64

$182.82 discount

UndervaluedFair: $348.46Overvalued

Intrinsic value data unavailable for PRE.

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

IQV3 strengths · Avg: 8.3/10
Return on EquityProfitability
21.4%9/10

Every $100 of equity generates 21 in profit

PEG RatioValuation
0.978/10

Growing faster than its price suggests

EPS GrowthGrowth
23.6%8/10

Earnings expanding 23.6% YoY

PRE1 strengths · Avg: 8.0/10
Price/BookValuation
2.0x8/10

Reasonable price relative to book value

Areas to Watch

IQV1 concerns · Avg: 2.0/10
Altman Z-ScoreHealth
1.332/10

Distress zone — elevated risk

PRE4 concerns · Avg: 3.3/10
Revenue GrowthGrowth
2.5%4/10

2.5% revenue growth

EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$361.14M3/10

Smaller company, higher risk/reward

Return on EquityProfitability
-31.8%2/10

ROE of -31.8% — below average capital efficiency

Comparative Analysis Report

WallStSmart Research

Bull Case : IQV

The strongest argument for IQV centers on Return on Equity, PEG Ratio, EPS Growth. Revenue growth of 10.3% demonstrates continued momentum. PEG of 0.97 suggests the stock is reasonably priced for its growth.

Bull Case : PRE

The strongest argument for PRE centers on Price/Book.

Bear Case : IQV

The primary concerns for IQV are Altman Z-Score.

Bear Case : PRE

The primary concerns for PRE are Revenue Growth, EPS Growth, Market Cap.

Key Dynamics to Monitor

IQV profiles as a value stock while PRE is a turnaround play — different risk/reward profiles.

IQV carries more volatility with a beta of 1.41 — expect wider price swings.

IQV is growing revenue faster at 10.3% — sustainability is the question.

IQV generates stronger free cash flow (561M), providing more financial flexibility.

Bottom Line

IQV scores higher overall (72/100 vs 35/100) and 10.3% revenue growth. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

IQVIA Holdings Inc

HEALTHCARE · DIAGNOSTICS & RESEARCH · USA

IQVIA, formerly Quintiles and IMS Health, Inc., is an American multinational company serving the combined industries of health information technology and clinical research. It is a provider of biopharmaceutical development and commercial outsourcing services, focused primarily on Phase I-IV clinical trials and associated laboratory and analytical services, including consulting services.

Prenetics Global Ltd

HEALTHCARE · DIAGNOSTICS & RESEARCH · USA

Prenetics Global Ltd (PRE) is a leading health technology innovator specializing in genetic and diagnostic testing, leveraging advanced technologies to provide essential health insights for consumers and healthcare professionals alike. The company boasts a comprehensive portfolio of cutting-edge genetic testing solutions and integrated digital health services, driving its robust international growth through strategic partnerships and an unwavering dedication to research and development. Positioned at the forefront of personalized medicine, Prenetics is well-equipped to meet the growing consumer demand for accessible and actionable health information, making it a compelling investment opportunity in the rapidly evolving healthcare sector.

Want to dig deeper into these stocks?